Your address will show here +12 34 56 78
Invest in Innovation
AVEX.AI Tracker Certificate
Offers investors exposure to the AVEX token.
  • Text Hover
A Revolutionary New Instrument for Investors
Gain Exposure to Blockchain-Derived Health Industry Assets through a Familiar Product
AVEX.AI is the first-ever tracker certificate issued via Swiss ISIN designed to participate in the world’s pioneering dynamic tokenized medical care market.

It is a structured product following Swiss guidelines, using a securitization pathway to introduce ISIN-wrapped digital tokens to traditional investors.

AVEX.AI offers a secure way of participating in blockchain-derived assets, which ensures that investors can take advantage of the new opportunities in this exponential space using a product that offers a high degree of ease and familiarity.

With AVEX.AI, there is no necessary learning curve or technological specialization required to invest in health industry cryptoassets. It combines the cutting-edge opportunity of blockchain with the simplicity and security of classic investment.

 



 

AVEX.AI Product Profile
The AVEX token is the blockchain-derived asset that allows consumers and other participants in the Biospheres network to transact within the Biospheres platform. It is designed to capture the value of the health innovation sector within a closed ecosystem. Biospheres is a borderless marketplace that accommodates billions of dollars in leading-edge health science, biotech products and medical offerings that offer solutions to some of the world’s most pressing health problems. The platform aims to address under- or unfunded projects looking to solve growing global concerns like Alzheimer’s Disease and cancer, rare diseases such as Amyotrophic Lateral Sclerosis (ALS), or resultant complications of medical treatments like organ rejection after transplantation, to name a few.

The AVEX token is also the first new digital asset to launch through a structured product available via Swiss ISIN. Opportunities for new token offerings were previously exclusive to a highly technical community that generated unprecedented returns for many early investors. With this new alternative investment product, we make it as easy as buying a stock as a means to introduce a new investor market into crypto and reduce the risks that have been associated with other differently-designed crypto offerings.
Name
AVEX.AI Tracker Certificate on Aevolve Token (AVEX)
ISIN Number
Upon Request
Classification
Tracker-Certificate (Code 1300) of the Swiss Derivative Map, as amended from time to time by the Swiss Structured Products Association (www.svsp-verband.ch)
Underlying Asset
AVEX token is the sole and exclusive cryptoasset that is used to purchase unique health tech products in BIOSPHERES, a tokenized marketplace for health innovation offerings.
Total Amount
USD 100’000’000.00 (Maximal Amount)
Issue Size
100’000 Certificates
Minimum Trade Size
10 Certificates and 1 Certificate thereafter
Subscription Period
To Be Announced
Issuing Company
FP ISSUER LIMITED (GUERNSEY)
Merging Traditional Finance with Health Innovation
Aevolve understands the importance of working with existing regulatory framework to provide clear-cut, simple and timely access to blockchain-derived assets. This has led to an innovation in the introduction of new cryptoassets, and a new blockchain model that provides direct access to patients and de-risks investors who wish to participate in it. The mutual benefits emerge through an unprecedented means of interaction of investors and innovators.

We capture the hidden value in health innovation space by allowing under-invested research and agile biotech companies to get their products funded outside of the traditional VC model, where they may be considered less of a priority, and where costs are skyrocketing to billions per commercialized drug. 

Through alternative financing, cutting-edge products are introduced faster and made more accessible to the public. 

By integrating this new blockchain financing strategy with trusted investment protocols, a new hybrid ecosystem is formed. This hybrid ecosystem brings the trillion-dollar derivative market into innovation financing, and enables investment opportunities and liquidity to flow between both sectors.
Safe
AVEX.AI is a classic investment that has all the properties of a legal security. This familiarity avoids technological mishaps in large-scale investing, especially for those who have not yet gone into blockchain-derived assets. Storage, custody, escrow, digital security are covered in the management of the underlying, and investors do not need to tackle issues such as self-management of private keys. One simply invests in a tracker certificate that follows the recognizable rules of the stock market.
Simple
AVEX.AI is a simple product that requires no learning curve or technological shift. Investors that are accustomed to traditional investment methods will find it an ideal entry point into the new, dynamic world of crypto markets.
Sustainable
AVEX.AI tracks the performance of AVEX in a marketplace that addresses a tremendous global need. Health and medical care after all, are universal and constitute an inexhaustible need. And the market for new treatments or solutions to diseases is persistent and enduring.

This presents a wide range of opportunities to partner with companies and researchers in order to constantly provide access to products and services that address countless medical needs of the world’s growing population. This setup offers greater possibility for renewable demand. Market relevance is sustained through steady on-boarding of new research efforts, independent or agile companies and new solutions. Innovation is the other driver of continuing value.
Structured Product
This is a first-in-the-world financial product that gives traditional financial managers exposure to a cryptotoken at it earliest stage. The regulatory and compliance landscape for cryptoassets is unclear and uncertain. This structured asset helps to break through the fear, uncertainty and doubt associated with a new technology.
Social Impact
This investment tool is geared towards social good, sustainability and future success by being a well-rounded mechanism that extends beyond marketing and financial performance. It was designed with social impact in mind.

Social benefits were ingrained in the business model from the start. The project benefits large communities by driving active donation market. The same marketplace that offers treatment reservations allows public donations to worthy causes in the health sector.

Today, ESG (Environmental, Social and Governance) Investing is considered an additional metric for investment strength. This model points to a more sustainable type of investment, relying on transformative social contributions that outlast short-term marketing and price-boosting efforts, and adding strong balance to a portfolio.
Solid
Pricing models and projections are based on actual, existing and viable solutions that will launch as part of Biospheres’ offerings. This is a high-practicality model for token utility addressing a high-value market and tremendous demand. It is a measurable, executable and reasonable cost model with realistic and achievable targets. With Year One partnership and offering targets secured, the project continues to on-board a lineup of multi-billion dollar offerings that will create a solid foundation for the token and the tracker.
  • Text Hover
  • Text Hover
  • Text Hover
  • Text Hover
  • Text Hover
SUBSCRIBE










Select country

Select language


Important Information

The information on this website is intended only for persons residing or having their registered office in Switzerland.

By using this website, you expressly confirm that you are a resident of the selected country. Aevolve AG explicitly declines any responsibility for the distribution of information or documents to natural or legal persons who provide incorrect information regarding their legal place of residence or registered office.

The financial products mentioned on this website are derivative financial instruments. They do not qualify as units of a collective investment scheme in the meaning of Article 7 et seqq. of the Swiss Federal Act on Collective Investment Schemes (CISA) and are therefore neither supervised by the Swiss Financial Market Supervisory Authority (FINMA) nor registered with FINMA. Investors do not benefit from the specific investor protection provided under the CISA.

Terms of use and legal information 

 

By using the Aevolve AG website (hereinafter “Website”), you confirm that you have understood and accept the legal information, important notes and terms of use presented here. If you do not accept the terms of use, please refrain from using this Website.

Proprietary information

 

All intellectual property rights (e.g. copyright, design and trademark rights) to the material presented on the Website belong to Aevolve AG or its platform partners, who will enforce these rights to the full extent of applicable laws. Any form of reproduction, republication or distribution of the content of this Website requires the written consent of Aevolve AG in Zurich (Switzerland) and the respective indication of the source.

No part of this Website is designed to grant any form of license or user rights to images, text, trademarks or logos. No act of downloading or copying content from the Website will transfer or bestow any legal entitlement to the Website’s software or materials.

Conflicts of interest

 

From time to time, the issuers and/or lead manager and/or their third-party agents may, for their own account or for the account of others, take positions in securities, currencies, financial instruments or other assets that serve as an underlying asset to the products on this Website. They may buy or sell these assets, act as market makers, and simultaneously operate as seller or as purchaser. The trading or hedging activities of the issuers and/or lead manager and/or their third-party agents may influence the price of an underlying asset and may influence whether or not the relevant barrier level is reached (if such a level exists).

Performance

 

Past performance is not an indication or guarantee of future performance of a product or underlying asset. The value of any investment may be subject to fluctuations and, in some circumstances, investors may not recover the original amount invested. Exchange rate fluctuations may also cause the value of an investment to rise or fall.

Selling restrictions

 

No action has been or will be taken to permit a public offering of the products or possession or distribution of any offering material in relation to the products in any jurisdiction, where such action for that purpose is required. Selling Restrictions Consequently, any offer, sale or delivery of the products, or distribution or publication of any offering material relating to the products, may only be made in or from any jurisdiction in compliance with applicable laws and regulations not imposing any obligations on the issuers or the lead manager. Possible limitations resulting from legal restrictions with regard to cross-border communication and cross-border business concerning the products and related information remain reserved. The most important jurisdictions where the products may not be publicly distributed are EEA, UK, Hong Kong and Singapore.

The products may not be offered or sold within the USA, or to or for the account or benefit of US persons (as defined in Regulation S).

Detailed information on selling restrictions is published in the respective issuance programme, which is published on this Website and at aevolve.health.

We are hiring

Are you looking for job?

We are a fairly small, flexible design studio that designs for print and web. We work flexibly with Send us your resume & portfolio